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Balamuthia mandrillaris is a rare cause of human infection, but when infections do occur, they result in high rates of morbidity
and mortality. A case of disseminated Balamuthia infection is presented. Early diagnosis and initiation of recommended therapy
are essential for increased chances of successful outcomes.
CASE REPORT
The patient was an 82-year-old white male with a history ofnecrobiosis lipoidica versus granuloma annulare of the right
hand who was admitted in April 2012 for acute onset of fevers,
chills, nausea, vomiting, lethargy, and altered mental status
(AMS). He initially presented to an outside-hospital emergency
department with a temperature of 38.5°C, a heart rate of 97 beats
per min, and oxygen saturation of 88% on room air. His oxygen
saturation improved with administration of nasal cannula oxy-
gen. A chest X-ray (CXR) procedure was performed and demon-
strated findings concerning for granulomatous disease. Due to his
condition, he was transferred to our tertiary care center for further
evaluation and treatment.
Per his family, he had been healthy and without complaints
prior to his current presentation. For approximately 15
months, he had been treated by a dermatologist for skin lesions
located on his right thigh and hand as well as left upper extrem-
ity (LUE) and abdomen. He had multiple skin biopsy speci-
mens from the right hand, LUE, and right thigh with negative
bacterial, acid-fast bacillus (AFB), and fungal analysis results.
During this period of time, he took itraconazole for 3 months
without clinical response and was thus started on prednisone.
All lesions resolved except those on his right hand. He was
treated with a 14-day course of doxycycline and cephalexin for
possible cellulitis of the right hand prior to this admission.
Previous workup included a negative syphilis screen and a nor-
mal angiotensin-converting enzyme (ACE) level (drawn for
possible sarcoidosis). A CXR performed at that time revealed
nonspecific interstitial changes.
A review of the patient’s symptoms was obtained from family
members given the patient’s AMS. Per their report, the patient
reported a headache but no neck pain or stiffness. He had no
history of mouth sores or genital ulcers and had a remote history
of shingles. He had had an episode of bronchitis 1 month prior to
admission (PTA) that was slow to improve but gradually resolved.
In terms of exposures, he had no history of international travel
but did have seawater exposure on the Gulf Coast of Alabama 1
month prior to admission. He had no pets but had been mowing
grass and spreading grass seed PTA. He had no known tick bites
but spent time outdoors using a metal detector for treasure hunt-
ing and digging in soil. Previously, he had taught a bible study
group in a prison but had no known tuberculosis (TB) exposure
and no previous TB testing.
In an initial physical examination, he was febrile to 38.2°C
and his oxygen saturation was 94% with 2 liters of oxygen
administered using a nasal cannula. He was initially agitated
and confused but progressed to somnolence over a period of 12
h. He had no cervical lymphadenopathy or nuchal rigidity.
Cardiac, pulmonary, and abdominal examination results were
unremarkable. On the right dorsal hand and proximal fingers,
there was a collection of erythematous punched-out ulcers
with overlying crusts that extended onto the palm at the 5th
metacarpal-phalangeal surface (Fig. 1A). His initial laboratory
values were significant for a total white blood cell (WBC) count
of 8,600/l with 88.3% neutrophils and 4.8% lymphocytes. He
also had a hemoglobin level of 13.1 g/dl, hematocrit of 37.7%,
sodium of 129 mmol/liter, albumin of 2.9 g/dl, creatinine of 1.3
mg/dl, and glucose of 256 g/dl.
A computed tomography (CT) scan of the head revealed age-
indeterminate infarcts in the anterior limb of the right internal
capsule, left parafalcine frontal lobe, and inferior left frontal lobe
thought likely to be chronic infarcts. A CXR showed diffuse, bilat-
eral opacities. A CT scan of the chest revealed diffuse centrilobular
nodules with intralobular septal thickening. Given his presenta-
tion and imaging findings, he was empirically started on intrave-
nous (i.v.) ceftriaxone and azithromycin for coverage of commu-
nity-acquired pneumonia.
On hospital day (HD) 1, staff members of the Infectious Dis-
ease department were consulted and the patient was empirically
started on treatment for meningoencephalitis, including i.v.
vancomycin, ceftriaxone, acyclovir, and trimethoprim-sulfame-
thoxazole (a reported but unknown penicillin allergy precluded
the use of ampicillin for coverage of a possible Listeria infection),
in addition to the antibiotics for pneumonia. A repeat examina-
tion performed at that time did reveal nuchal rigidity. Cerebrospi-
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nal fluid (CSF) analysis via lumbar puncture revealed an opening
pressure of 21 cm H2O, protein at 54 mg/dl, and glucose at 86
mg/dl. A cell count was remarkable for 14 WBCs (57% lympho-
cytes, 3% neutrophils, and 40% monocytes). No organisms were
identified on Gram stain. Dermatology analyses were also per-
formed using skin biopsy specimens and cultures of the patient’s
right hand.
On HD 2, the preliminary report of the results of analyses of
the patient’s skin biopsy specimen revealed a dense mixed
acute and chronic dermal inflammatory infiltrate. Scattered
organisms, morphologically compatible with ameba, were
noted within lacunar spaces (Fig. 1B; original magnification,
400). The organisms showed granular to vacuolated cyto-
plasm with irregular contours and contained enlarged nuclei
with large central karyosomes (Fig. 1C; original magnification,
1,000). The patient was therefore empirically started on lipo-
somal amphotericin and voriconazole for coverage of dissem-
inated amebiasis and amebic encephalitis (AE). All other anti-
biotics except for azithromycin were discontinued. Despite
treatment with broad-spectrum antibiotics, the patient contin-
ued to become increasingly obtunded, eventually requiring
transfer to the intensive care unit (ICU) on HD 3 for closer
monitoring and worsening hypoxia, intermittently requiring
increased oxygen supplementation.
On HD 4, the Centers for Disease Control and Prevention
(CDC) were contacted for further therapeutic options. CDC rec-
ommended combination therapy shown to have efficacy in previ-
ous cases, including pentamidine, sulfadiazine, flucytosine, flu-
conazole (or itraconazole), and azithromycin (or clarithromycin)
as well as miltefosine, which at the time required approval by the
Food and Drug Administration (FDA) and overseas delivery be-
fore it could be used (1–4). As there was not yet a definitive iden-
tification of the ameba species, sulfadiazine at 1.5 g every 6 h,
pyrimethamine at 200 mg once and then 75 mg daily, and leuco-
vorin at 25 mg daily were added, based on case reports of success-
ful treatment of Acanthamoeba encephalitis (5). His azithromycin
FIG 1 Dermatologic presentation and pathology. (A) Erythematous punched-out ulcers with overlying crusts on the right dorsal hand. (B) Histopathology from
the right hand showing a dense mixed acute and chronic dermal inflammatory infiltrate and scattered amebic trophozoites within lacunar spaces (arrows).
(Original magnification, 400). (C) High-power view of an amebic organism demonstrating a granular to vacuolated cytoplasm with irregular contours
(pseudopods) containing a nucleus with a large central karyosome (arrow). (Original magnification, 1,000). (D) Low-power view of immunofluorescence from
skin biopsy specimen. (Original magnification, 100). (E) High-power view of immunofluorescence from skin biopsy specimen with visible amoebic organisms.
(Original magnification, 1,000).
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dose was increased to 1,800 mg daily as well. At this time, milte-
fosine was ordered.
Given the persistent AMS and concern for AE, magnetic
resonance imaging (MRI) of the brain was performed, which
revealed multiple parenchymal supra- and infratentorial
rounded lesions with surrounding white matter edema and
faint enhancement. The largest lesions were in the left posterior
temporal lobe. Other lesions were seen in the left dorsal pons
and left frontal lobe. Radiology results indicated that these le-
sions were likely to be infectious in nature. Neurosurgery staff
members were consulted on HD 4 for urgent biopsy of the
patient’s largest brain mass. At this time, the patient’s sodium
level continued to decrease to a nadir of 121 mmol/liter. Be-
cause of his worsening hyponatremia and the small size of the
lesions, they deferred brain biopsy and recommended a repeat
MRI for evaluation of progression of his lesions. Also, because
of the patient’s worsening respiratory symptoms, he under-
went evaluation using bronchoscopy. The results of analysis of
the bronchoalveolar lavage (BAL) fluid were negative for Legio-
nella pneumophila, Pneumocystis jirovecii, acid-fast bacilli, viruses,
and fungal etiologies. Gram-negative rods were visible in the BAL
fluid Gram stain, so cefepime was added to his antibiotic regimen.
On HD 5, the patient’s condition remained unchanged with no
signs of improvement. Following CDC recommendations, flucy-
tosine at 1,750 mg administered i.v. every 12 h (q12h) was added
to his treatment regimen. Miltefosine was being held in Customs
at that time, pending FDA release.
On HD 6, a repeat MRI demonstrated increases in the number
and size of prior lesions. These lesions also showed perilesional
edema and faint enhancement. At that time, the neurosurgery
staff members planned to perform a biopsy with radiologic guid-
ance on HD 10 as his serum sodium normalized.
On HD 7, the bacterial culture from the BAL fluid grew “a
few” Pseudomonas aeruginosa bacteria which were sensitive to
cefepime. The patient’s inability to handle secretions became
more pronounced, and his clinical status continued to deteriorate,
requiring increasing oxygen and low-dose vasopressor support. A
family meeting was held to discuss goals of care; the family decided
to continue antibiotics but to change his code status to “Do Not
Resuscitate or Intubate.”
On HD 8, CDC reported preliminary identification of ameba
forms on a skin biopsy specimen which likely represented Bal-
amuthia. The pyrimethamine and leucovorin treatments were dis-
continued, and the patient was started on pentamidine at 300 mg
i.v. daily.”
On HD 9, the patient began to have periods of apnea and ex-
pired with family at the bedside.
The family agreed to proceed with a limited autopsy of the
brain only. A postmortem gross examination revealed numerous
red to brown soft lesions involving bilateral parietal, frontal, and
temporal lobes, left pons and basal ganglia, and cerebellum, pre-
dominantly in subcortical white matter, with many lesions ex-
tending to the gray-white junction. Histopathologic examination
revealed the granulomatous nature of the lesions, with predomi-
nantly cyst forms and occasional trophozoites, consistent with an
amebic infection (Fig. 2). Additionally, purulent and granuloma-
tous inflammation was noted in many subpial and perivascular
spaces. Real-time PCR assays performed on fresh-frozen autopsy
brain material determined the amebic species to be Balamuthia
mandrillaris. The CDC performed immunofluorescent staining of
the skin biopsy specimen, which was positive for Balamuthia man-
drillaris (Fig. 1D and E). The final diagnosis was disseminated
Balamuthia mandrillaris infection.
Microbiology. Balamuthia mandrillaris is a free-living ameba
that lives in soil, dust, and water (6). The species name derives
from the first site from which it was isolated in 1986 —the brain of
a mandrill. The first human case of Balamuthia-associated gran-
ulomatous encephalitis was described in 1990. In the laboratory,
Balamuthia feeds on small ameba but not bacteria, which makes
its growth in the laboratory challenging. Cultivation of this organ-
ism in the laboratory requires axenic culture or growth in mam-
malian cell cultures (7). The exact pathogenesis of Balamuthia is
incompletely defined at this time, although cell-to-cell contact
appears necessary for this process, and the organism may have an
affinity for binding to the extracellular matrix (2, 7–9). However,
human infection appears to begin with either inhalation or percu-
taneous inoculation of Balamuthia cysts or trophozoites. The or-
ganisms are then believed to either migrate through tissue or via
hematogenous spread to the location or locations where disease
becomes manifest, which can include the brain and skin most
commonly but other organs as well. A mouse model of Bal-
amuthia encephalitis proposes the following as one possible mode
of infection: the organism is inhaled through the nasal passages,
adheres to the nasal epithelium, and then travels along the olfac-
tory nerve into the central nervous system (CNS) (10).
Epidemiology. Balamuthia has been identified in infections in
both immunocompromised and immunocompetent patients.
There is no clear predilection based on age or sex, but cases have
been reported from individuals at the extremes of age, and the
earliest reported cases were in patients with AIDS or substance
abuse disorders (2, 11). While there is an overrepresentation of
Hispanic ethnicity among reported cases, the cause of this associ-
ation is not understood and may be related to surveillance, expo-
sure, biology, or other factors or combinations of factors (9, 12).
Transmission through organ transplantation has also occurred
(13, 14).
Clinical presentation. Balamuthia mandrillaris has two pri-
mary clinical presentations, cutaneous and granulomatous ame-
bic encephalitis (GAE), each of which may have a prodrome of
weeks to months. There are also case reports of sinus infections
and pulmonary involvement, typically, in the form of abscesses
(7). Patients may present with isolated cutaneous findings or typ-
ical encephalopathy/encephalitis symptoms. The latter presenta-
tion may also include meningeal signs (9). The cutaneous mani-
festations can vary from ecthyma-like lesions to erythematous
plaques.
The pulmonary findings in our case represent a presentation
different from those seen in other cases described in the literature.
Although we do not have a definitive tissue diagnosis for his pul-
monary process, it likely represented disseminated amebic infec-
tion given the presence of the organism in two other anatomic
locations (skin and brain).
Diagnosis. The diagnostic difficulty derives from the nonspe-
cific presentation, which may not suggest amebic infection early in
the disease course. A thorough exposure history, skin examina-
tion, and neurologic assessment may suggest inclusion of this en-
tity in the differential diagnosis. If neurologic symptoms are pres-
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ent, brain MRI results may be helpful and may show space-
occupying, ring-enhancing lesions. If cutaneous involvement is
present, a skin biopsy specimen can be diagnostic if trophozoite
forms are seen. Balamuthia species, although difficult to distin-
guish from Acanthamoeba species in hematoxylin and eosin
(H&E) staining, may have 2 to 3 nucleoli visible. Immunofluores-
cence staining, PCR, and an experimental serologic test can be
performed at CDC to distinguish between Balamuthia and Acan-
thamoeba species. A cerebrospinal fluid examination may reveal
lymphocytic pleocytosis, elevated protein levels, normal or low
glucose levels, and normal or mildly elevated opening pressure
levels. Brain biopsy specimens may show both trophozoite and
cyst forms of Balamuthia that show positive immunofluorescent
staining results.
Consideration of Balamuthia infection early in the disease
course is the most important element of a diagnostic workup.
Once the diagnosis is included in the differential, further diagnos-
tic workup, treatment guidance, and prompt access to miltefosine
can be obtained by contacting the CDC Emergency Operations
Center at (770) 488-7100. Additionally, further information
about the clinical features of Balamuthia and its basic workup is
available on the CDC website at http://www.cdc.gov/parasites
/balamuthia/health_professionals/index.html.
Treatment/prognosis. Prognosis is poor, in part because the
diagnosis is often not considered until late in the disease course.
There is no clear standard therapy for infections with B. mandril-
laris. Pentamidine, flucytosine, fluconazole, and sulfadiazine plus
either azithromycin or clarithromycin (combined with surgical
resection if CNS lesions are present) have been used successfully in
a few cases (2). Additionally, miltefosine, an agent used to treat
FIG 2 Central nervous system lesions. (A) MRI axial fluid-attenuated inversion recovery (FLAIR) image demonstrating multiple focal, rounded hyperintense
lesions in the pons, cerebellum, and occipital lobes. (B) Gross section of the pons and cerebellum; softened granular lesion in the pons (see arrow). (C)
Microscopic examination of the pontine lesion; prominent granulomatous inflammation (yellow asterisk) in abundant necrotic background. A single amebic
cyst is seen (black arrow) in the mid-lower field of the picture.
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leishmaniasis, has demonstrated some in vitro effect on Bal-
amuthia infections and has been used successfully in combination
therapy of Balamuthia GAE and skin infections (4, 15). Miltefos-
ine is not readily available in the United States but can now be
obtained directly from the CDC under an FDA-approved investi-
gational new drug protocol for treatment of free-living ameba
infections (16). Amphotericin B, trimethoprim-sulfamethoxazole
(TMP-SMX), and polymyxin B have shown little to no in vitro
effects on Balamuthia (7). Other work suggests that cyst formation
in brain tissue may be hindered by ketoconazole, cytochalasin D,
and cycloheximide (17).
In summary, Balamuthia mandrillaris infection is a rare, but
important, cause of encephalitis and cutaneous infection. It is dif-
ficult to diagnose, and early tissue biopsy is extremely important.
This disease manifests with a very high mortality rate. Treatment
is poorly defined, but early diagnosis, prompt ameba-specific
treatment, and increased availability of miltefosine through the
CDC may have a positive effect on outcomes in the future.
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